Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
1.
Br J Clin Pharmacol ; 90(9): 2271-2279, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-38866400

RESUMEN

AIMS: The South Korean government implemented the narcotics information management system (NIMS) on 18 May 2018 to manage benzodiazepine receptor agonists (BzRAs) and narcotics effectively and establish a reporting mechanism for these drugs. This study assessed the effects of NIMS on inappropriate use of BzRAs. METHODS: Using national patient sample data from 2016 to 2020, we analysed adult outpatients who were prescribed oral BzRAs. We conducted a time series and segmented regression analysis using selected indicators to analyse the monthly variations related to the inappropriate use of these medications. RESULTS: The study revealed no significant changes in the indicators of inappropriate BzRA use following the NIMS implementation. Contrary to expectations, there was a significant increase in the proportion of patients exceeding defined daily dose (DDD) and in those receiving concurrent prescriptions of multiple BzRAs, following the implementation of NIMS. The immediate impact of the COVID-19 pandemic was an increase in DDD exceedance; however, overall, this did not significantly affect BzRA use. CONCLUSIONS: The introduction of NIMS did not significantly enhance the management of BzRA misuse. Additional measures, including continuous monitoring, system improvements and comprehensive education for prescribers and patients, are recommended to ensure the appropriate use of psychotropic medications.


Asunto(s)
Agonistas de Receptores de GABA-A , Prescripción Inadecuada , Humanos , República de Corea , Masculino , Femenino , Adulto , Persona de Mediana Edad , Prescripción Inadecuada/estadística & datos numéricos , Prescripción Inadecuada/prevención & control , Agonistas de Receptores de GABA-A/uso terapéutico , Agonistas de Receptores de GABA-A/administración & dosificación , Agonistas de Receptores de GABA-A/efectos adversos , Narcóticos/uso terapéutico , Anciano , Pautas de la Práctica en Medicina/estadística & datos numéricos , Pautas de la Práctica en Medicina/normas , COVID-19 , Benzodiazepinas/uso terapéutico , Benzodiazepinas/administración & dosificación , Adulto Joven
2.
J Immunol ; 198(4): 1484-1491, 2017 02 15.
Artículo en Inglés | MEDLINE | ID: mdl-28093521

RESUMEN

Oncostatin M (OSM) is a pleiotropic cytokine and a member of the IL-6 family. It has both proinflammatory and anti-inflammatory functions and is involved in the activation of STAT3 and STAT5. Rheumatoid arthritis is an autoimmune disease that causes chronic and excessive inflammation. Rheumatoid arthritis can lead to induction of Th17 cells, which express IL-17. The aim of this study was to measure the effects of OSM on the proliferation of regulatory T cells and Th17 cells from mice. IL-2 immune complex suppressed the development of collagen-induced arthritis in mice and altered the regulatory T/Th17 cell balance by increasing OSM expression. OSM mitigated the proliferation of Th17 cells and decreased the expression of IL-17 and IL-21. It promoted the activation of suppressor of cytokine signaling 3 (SOCS3), STAT3, and STAT5. Inhibition of SOCS3, STAT3, and STAT5 lessened the OSM-induced reduction in proliferation of Th17 cells. These observations suggest that OSM can inhibit Th17 differentiation by reciprocally controlling SOCS3, STAT3, and STAT5.


Asunto(s)
Linfocitos T CD4-Positivos/inmunología , Interleucina-17/genética , Oncostatina M/fisiología , Proteína 3 Supresora de la Señalización de Citocinas/genética , Linfocitos T Reguladores/inmunología , Células Th17/inmunología , Animales , Artritis Experimental , Linfocitos T CD4-Positivos/efectos de los fármacos , Diferenciación Celular/efectos de los fármacos , Colágeno/administración & dosificación , Regulación hacia Abajo , Regulación de la Expresión Génica , Interleucina-17/inmunología , Interleucina-2/inmunología , Interleucinas/genética , Interleucinas/inmunología , Ratones , Oncostatina M/genética , Oncostatina M/farmacología , Factor de Transcripción STAT3/genética , Factor de Transcripción STAT3/metabolismo , Factor de Transcripción STAT5/genética , Factor de Transcripción STAT5/metabolismo , Transducción de Señal/efectos de los fármacos , Proteína 3 Supresora de la Señalización de Citocinas/inmunología , Linfocitos T Reguladores/efectos de los fármacos , Células Th17/efectos de los fármacos
3.
J Immunol ; 198(7): 2661-2670, 2017 04 01.
Artículo en Inglés | MEDLINE | ID: mdl-28242651

RESUMEN

Circulating autoantibodies and immune complex deposition are pathological hallmarks of systemic lupus erythematosus (SLE). B cell differentiation into plasma cells (PCs) and some T cell subsets that function as B cell helpers can be therapeutic targets of SLE. Mechanistic target of rapamycin (mTOR) signaling is implicated in the formation of B cells and germinal centers (GCs). We assessed the effect of metformin, which inhibits mTOR, on the development of autoimmunity using Roquinsan/san mice. Oral administration of metformin inhibited the formation of splenic follicles and inflammation in kidney and liver tissues. It also decreased serum levels of anti-dsDNA Abs without affecting serum glucose levels. Moreover, metformin inhibited CD21highCD23low marginal zone B cells, B220+GL7+ GC B cells, B220-CD138+ PCs, and GC formation. A significant reduction in ICOS+ follicular helper T cells was found in the spleens of the metformin-treated group compared with the vehicle-treated group. In addition, metformin inhibited Th17 cells and induced regulatory T cells. These alterations in B and T cell subsets by metformin were associated with enhanced AMPK expression and inhibition of mTOR-STAT3 signaling. Furthermore, metformin induced p53 and NF erythroid-2-related factor-2 activity in splenic CD4+ T cells. Taken together, metformin-induced alterations in AMPK-mTOR-STAT3 signaling may have therapeutic value in SLE by inhibiting B cell differentiation into PCs and GCs.


Asunto(s)
Autoinmunidad/efectos de los fármacos , Diferenciación Celular/efectos de los fármacos , Hipoglucemiantes/farmacología , Lupus Eritematoso Sistémico/inmunología , Metformina/farmacología , Células Plasmáticas/efectos de los fármacos , Proteínas Quinasas Activadas por AMP/efectos de los fármacos , Proteínas Quinasas Activadas por AMP/inmunología , Animales , Linfocitos B/efectos de los fármacos , Linfocitos B/inmunología , Western Blotting , Diferenciación Celular/inmunología , Separación Celular , Modelos Animales de Enfermedad , Citometría de Flujo , Centro Germinal/efectos de los fármacos , Centro Germinal/inmunología , Inmunohistoquímica , Masculino , Ratones , Microscopía Confocal , Células Plasmáticas/inmunología , Factor de Transcripción STAT3/efectos de los fármacos , Factor de Transcripción STAT3/inmunología , Transducción de Señal/efectos de los fármacos , Transducción de Señal/inmunología , Serina-Treonina Quinasas TOR/efectos de los fármacos , Serina-Treonina Quinasas TOR/inmunología , Ubiquitina-Proteína Ligasas/deficiencia
4.
J Transl Med ; 14(1): 191, 2016 06 28.
Artículo en Inglés | MEDLINE | ID: mdl-27350539

RESUMEN

BACKGROUND: Foxp3 is a key regulator of the development and function of regulatory T cells (Tregs), and its expression is thought to be T cell-restricted. We found that B cells in mice can express Foxp3 and B cells expressing Foxp3 may play a role in preventing the development of collagen-induced arthritis (CIA) in DBA/1J mice. METHODS: Foxp3 expression was modulated in CD19(+) B cells by transfection with shRNA or using an over-expression construct. In addition, Foxp3-transfected B cells were adoptively transferred to CIA mice. We found that LPS or anti-IgM stimulation induced Foxp3 expression in B cells. Foxp3-expressing B cells were found in the spleens of mice. RESULTS: Over-expression of Foxp3 conferred a contact-dependent suppressive ability on proliferation of responder T cells. Down-regulation of Foxp3 by shRNA caused a profound induction in proliferation of responder T cells. Adoptive transfer of Foxp3(+)CD19(+) B cells attenuated the clinical symptoms of CIA significantly with concomitant suppression of IL-17 production and enhancement of Foxp3 expression in CD4(+) T cells from splenocytes. CONCLUSION: Our data indicate that Foxp3 expression is not restricted to T cells. The expression of Foxp3 in B cells is critical for the immunoregulation of T cells and limits autoimmunity in a mouse model.


Asunto(s)
Traslado Adoptivo , Artritis Experimental/inmunología , Enfermedades Autoinmunes/inmunología , Enfermedades Autoinmunes/patología , Linfocitos B Reguladores/inmunología , Factores de Transcripción Forkhead/metabolismo , Linfocitos T Reguladores/inmunología , Células Th17/inmunología , Animales , Artritis Experimental/patología , Comunicación Celular , Línea Celular Tumoral , Proliferación Celular , Inmunoglobulina M/metabolismo , Terapia de Inmunosupresión , Lipopolisacáridos , Masculino , Ratones Endogámicos DBA , Bazo/patología , Transfección
6.
Mediators Inflamm ; 2014: 973986, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25214721

RESUMEN

Metformin is widely used to suppress certain functions of the cells found in diseases including diabetes and obesity. In this study, the effects of metformin on downregulating IL-17-producing T (Th17) cells, activating and upregulating regulatory T (Treg) cells, suppressing osteoclastogenesis, and clinically scoring collagen-induced arthritis (CIA) were investigated. To evaluate the effect of metformin on CIA, mice were orally fed with either metformin or saline as control three times a week for nine weeks. Histological analysis of the joints was performed using immunohistochemistry and Th17 cells and Treg cells of the spleen tissue were examined by confocal microscopy staining. Metformin mitigated the severity of CIA, reduced serum immunoglobulin concentrations, and reciprocally regulated Th17/Treg axis. Also, metformin treatment of normal cells cultured in Th17 conditions decreased the number of Th17 cells and increased the number of Treg cells. Metformin decreased gene expression and osteoclastogenic activity in CIA and normal mice. These results indicate that metformin had immunomodulatory actions influencing anti-inflammatory action on CIA through the inhibition of Th17 cell differentiation and the upregulation of Treg cell differentiation along with the suppression of osteoclast differentiation. Our results suggest that metformin may be a potential therapeutic for rheumatoid arthritis.


Asunto(s)
Artritis Experimental/tratamiento farmacológico , Artritis Experimental/inmunología , Metformina/uso terapéutico , Linfocitos T Reguladores/efectos de los fármacos , Células Th17/efectos de los fármacos , Animales , Artritis Reumatoide/tratamiento farmacológico , Artritis Reumatoide/inmunología , Diferenciación Celular/efectos de los fármacos , Interleucina-17/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Osteoclastos/efectos de los fármacos
8.
J Leukoc Biol ; 100(3): 559-68, 2016 09.
Artículo en Inglés | MEDLINE | ID: mdl-26957211

RESUMEN

The green tea polyphenol epigallocatechin-3-gallate is a potent antioxidant. Here, we describe the effects of epigallocatechin-3-gallate on T cell differentiation and osteoclast differentiation in an animal model of arthritis. Mice with collagen-induced arthritis were injected intraperitoneally with epigallocatechin-3-gallate, 3 times/wk after the primary immunization. Surface markers of T helper 17 cells and regulatory T cells were analyzed by flow cytometry. Flow cytometry, Western blotting, and enzyme-linked immunosorbent assays were used to evaluate the effect of epigallocatechin-3-gallate on cell signaling in the collagen-induced arthritis model. Epigallocatechin-3-gallate decreased the arthritis index and showed protective effects against joint destruction in collagen-induced arthritis mice. The expression of cytokines, oxidative stress proteins, and phosphorylated-signal transducer and activator of transcription-3, 705 and 727, were significantly less in mice treated with epigallocatechin-3-gallate than it was in controls. Epigallocatechin-3-gallate reduced the expression of osteoclast markers in vitro and in vivo relative to the control, and the antiosteoclastic activity was observed in epigallocatechin-3-gallate-treated, interferon-γ knockout mice. The proportion of forkhead box protein 3-positive regulatory T cells was increased in the spleens of mice treated with epigallocatechin-3-gallate compared with control mice, whereas the proportion of T helper 17 cells was reduced. In vitro, the expression of nuclear respiratory factor 2, heme oxygenase-1, and extracellular signal-regulated kinase was increased significantly by epigallocatechin-3-gallate. We demonstrated that the administration of epigallocatechin-3-gallate attenuated the symptoms of arthritis, inhibited osteoclastogenesis and T helper 17 cell activation, and increased the number of regulatory T cells. At the molecular level, the antiarthritic effects of epigallocatechin-3-gallate may be due to induction of phosphorylated-extracellular signal-regulated kinase, nuclear respiratory factor 2, and heme oxygenase-1 and inhibition of signal transducer and activator of transcription-3 activation.


Asunto(s)
Antioxidantes/farmacología , Artritis Experimental/prevención & control , Enfermedades Autoinmunes/prevención & control , Catequina/análogos & derivados , Factor de Transcripción STAT3/antagonistas & inhibidores , Linfocitos T Reguladores/inmunología , Células Th17/inmunología , Animales , Artritis Experimental/inmunología , Artritis Experimental/metabolismo , Enfermedades Autoinmunes/inmunología , Enfermedades Autoinmunes/metabolismo , Catequina/farmacología , Diferenciación Celular/efectos de los fármacos , Células Cultivadas , Modelos Animales de Enfermedad , Masculino , Ratones , Ratones Endogámicos DBA , Ratones Noqueados , Osteoclastos/citología , Osteoclastos/efectos de los fármacos , Osteoclastos/inmunología , Osteogénesis/efectos de los fármacos , Transducción de Señal
9.
Transl Res ; 173: 115-130, 2016 07.
Artículo en Inglés | MEDLINE | ID: mdl-27126953

RESUMEN

Acute graft-versus-host disease (aGVHD), caused by donor T cell-mediated injury to host tissues, is a problem in allogeneic bone marrow transplantation. The transition from naïve to effector T cells is accompanied by shift in metabolism main pathway; from glucose oxidative phosphorylation to aerobic glycolysis. Adenosine monophosphate-activated protein kinase (AMPK) is a serine/threonine kinase that is a metabolic sensor that helps maintain cellular energy homeostasis. Although AMPK activation can exert anti-inflammatory properties by negatively regulating pro-inflammatory mediators, its role as a therapeutic potential of graft-versus-host disease development remains unclear. In this study, we found that the intraperitoneal administration of metformin, which activates AMPK signaling significantly, ameliorated the clinical severity of aGHVD and lethality. This was associated with reductions in type I T helper (Th1) and Th17 and rises in Th2 and regulatory T (Treg) cell. The enhanced signal transducer and activator of transcription 3 activation noted during the development of aGVHD was reduced by metformin treatment. Furthermore, metformin-treated Th17 cells became converted into Treg cells via enhanced autophagy. The reduction in mortality associated with metformin treatment was associated with inhibition of the mammalian target of rapamycin/signal transducer and activator of transcription 3 pathway. These results suggest that metformin might be of significant use in the treatment of patients with aGVHD.


Asunto(s)
Adenilato Quinasa/metabolismo , Autofagia/efectos de los fármacos , Enfermedad Injerto contra Huésped/tratamiento farmacológico , Metformina/uso terapéutico , Factor de Transcripción STAT3/metabolismo , Linfocitos T Reguladores/metabolismo , Serina-Treonina Quinasas TOR/metabolismo , Células Th17/metabolismo , Animales , Diferenciación Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Modelos Animales de Enfermedad , Regulación hacia Abajo/efectos de los fármacos , Activación Enzimática/efectos de los fármacos , Enfermedad Injerto contra Huésped/inmunología , Enfermedad Injerto contra Huésped/patología , Humanos , Activación de Linfocitos/efectos de los fármacos , Recuento de Linfocitos , Metformina/farmacología , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Fosforilación/efectos de los fármacos , Bazo/efectos de los fármacos , Bazo/patología , Linfocitos T Reguladores/efectos de los fármacos , Células Th17/efectos de los fármacos
10.
Arthritis Rheumatol ; 66(7): 1768-78, 2014 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-24644005

RESUMEN

OBJECTIVE: Intravenous immunoglobulin (IVIG) is used as a therapeutic agent in various autoimmune diseases. The aims of this study were to investigate the therapeutic effects of IVIG on collagen-induced arthritis (CIA) and identify the mechanism responsible for any therapeutic effects. METHODS: IVIG was administered to mice with CIA, and the in vivo effects were determined. Th17 and Treg cell frequencies were analyzed by flow cytometry, and cytokine levels in the supernatant were measured by enzyme-linked immunosorbent assay. Subpopulations of T cells and B cells in the spleen were assessed by confocal microscopy. RESULTS: The arthritis severity score and incidence of arthritis were lower in mice treated with IVIG compared with untreated mice. Histopathologic analysis showed less joint damage in mice treated with IVIG. The expression of proinflammatory cytokines, specific type II collagen antibodies, and osteoclast markers was significantly reduced in mice treated with IVIG. Administration of IVIG induced increased FoxP3 expression and inhibited Th17 cell development. The number of FoxP3+ Treg cells was increased, and the number of Th17 cells was decreased in the spleens of mice treated with IVIG. The number of FoxP3+ follicular helper T cells was increased, and subsequent maturation of germinal center B cells was inhibited by IVIG. In addition, IVIG up-regulated interleukin-10 (IL-10) and Fcγ receptor IIB expression. The treatment effects of IVIG on arthritis were lost in IL-10-knockout mice. CONCLUSION: These results showed that IVIG has therapeutic effects by modulating CD4+ T cell differentiation. The therapeutic effects of IVIG are dependent on IL-10.


Asunto(s)
Artritis Experimental/tratamiento farmacológico , Enfermedades Autoinmunes/tratamiento farmacológico , Inmunoglobulinas Intravenosas/farmacología , Interleucina-10/inmunología , Linfocitos T Reguladores/efectos de los fármacos , Células Th17/efectos de los fármacos , Animales , Artritis Experimental/inmunología , Enfermedades Autoinmunes/inmunología , Linfocitos B/citología , Linfocitos B/inmunología , Citometría de Flujo , Masculino , Ratones , Ratones Endogámicos DBA , Receptores de IgG/genética , Receptores de IgG/inmunología , Índice de Severidad de la Enfermedad , Linfocitos T Reguladores/citología , Linfocitos T Reguladores/inmunología , Células Th17/citología , Células Th17/inmunología , Regulación hacia Arriba/efectos de los fármacos , Regulación hacia Arriba/inmunología
11.
Arthritis Res Ther ; 15(1): R31, 2013 Feb 20.
Artículo en Inglés | MEDLINE | ID: mdl-23421940

RESUMEN

INTRODUCTION: Fibroblast-like synoviocytes (FLSs) are a major cell population of the pannus that invades adjacent cartilage and bone in rheumatoid arthritis (RA). The study was undertaken to determine the effect of interleukin-17 (IL-17) on the survival and/or proliferation of FLSs from RA patients and to investigate whether signal tranducer and activator of transcription 3 (STAT3) is implicated in this process. METHODS: Bcl-2 and Bax expression in FLSs was determined using the real-time PCR and western blot analysis. The expression of Bcl-2 and phosphoSTAT3 in synovial tissues was investigated by confocal microscope. Apoptosis of FLSs was detected by Annexin V/propidium iodide staining and/or phase contrast microscopy. The proliferation of FLSs was determined by CCK-8 ELISA assay. RESULTS: The pro-apoptotic Bax is decreased and anti-apoptotic Bcl-2 is increased in FLSs from RA patients compared with those from patients with osteoarthritis (OA). IL-17 upregulated the expression of Bcl-2 in FLSs from RA patients, but not in FLSs from OA patients. STAT3 was found to mediate IL-17-induced Bcl-2 upregulation in FLSs from RA patients. Additionally, IL-17 promoted the survival and proliferation of FLSs from RA patients. Most importantly, treatment with STAT3 inhibitor reversed the protective effect of IL-17 on FLSs apoptosis induced by sodium nitroprusside (SNP). CONCLUSIONS: Our data demonstrate that STAT3 is critical in IL-17-induced survival of FLS from RA patients. Therefore, therapeutic strategies that target the IL-17/STAT3 pathway might be strong candidates for RA treatment modalities.


Asunto(s)
Artritis Reumatoide/metabolismo , Interleucina-17/metabolismo , Células Madre Mesenquimatosas/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2/biosíntesis , Factor de Transcripción STAT3/metabolismo , Artritis Reumatoide/inmunología , Artritis Reumatoide/patología , Western Blotting , Supervivencia Celular , Ensayo de Inmunoadsorción Enzimática , Fibroblastos/inmunología , Fibroblastos/metabolismo , Humanos , Inmunohistoquímica , Interleucina-17/inmunología , Células Madre Mesenquimatosas/inmunología , Microscopía Confocal , Reacción en Cadena en Tiempo Real de la Polimerasa , Factor de Transcripción STAT3/inmunología , Membrana Sinovial/citología
12.
J Colloid Interface Sci ; 342(2): 311-9, 2010 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-19932489

RESUMEN

SEIRA, SERS, TPD and DFT were used to study 4-nitrophenol (4NP), 3-nitrophenol (3NP) and 2-nitrophenol (2NP) adsorption on nanoscale silver films/powder. SERS and DFT demonstrated that 4NP adsorbed as the 4-nitrophenolate ion. SEIRA results revealed that a 4NP multilayer condensed differently using deposition solvents with and without polar bonds. 3NP and 2NP adsorption were not altered by the polar properties of the solvent. The nanoscale properties of the silver films/powder were shown to impact how the polar properties of the deposition solvent altered nitrophenol adsorption. In the SEIRA spectra of 4NP and 3NP a C=O stretch was observed above 1700cm(-1) using a highly volatile n-pentane deposition solvent. No other solvent yielded such a peak for 4NP or 3NP adsorption including n-heptane. 2NP had a C=O stretch regardless of deposition solvent. A C=O stretch confirmed nitrophenol ionization in the monolayer and pointed toward the significance of resonance in NP adsorption. 2NP never formed a multilayer at high exposures as demonstrated using TPD and SEIRA. Results of this work will have environmental implications and will aid biochemical and industrial applications where phenolic compounds are employed.


Asunto(s)
Nanoestructuras/química , Nitrofenoles/química , Plata/química , Adsorción , Isomerismo , Modelos Moleculares , Análisis Espectral/métodos
13.
Spectrochim Acta A Mol Biomol Spectrosc ; 74(1): 104-12, 2009 Sep 15.
Artículo en Inglés | MEDLINE | ID: mdl-19520600

RESUMEN

Surface-enhanced Raman Spectroscopy (SERS), surface-enhanced infrared absorption spectroscopy (SEIRA), temperature-programmed desorption (TPD), and density functional theory were used to characterize the adsorption properties of the hydroxybenzoic acid (HBA) isomers including ortho-hydroxybenzoic acid (OHA), meta-hydroxybenzoic acid (MHA), and para-hydroxybenzoic acid (PHA) using various deposition solvents with different polar properties. SERS typically enhances the Raman shifts of the monolayer, while SEIRA is a longer range effect, often providing vibrational enhancement to both the monolayer and multilayer. TPD analysis showed that OHA adsorption to silver is weaker than MHA/PHA, most likely as a result of the strong OHA intramolecular hydrogen-bonding. SERS and SEIRA demonstrated that OHA ionized efficiently in the monolayer and multilayer independent of the solvent polarity because of OHA's low pK(a) (2.98). MHA/PHA ionized better than OHA in the multilayer in less polar deposition solvents, and a decrease in the polarity of the deposition solvent created additional ordering in the MHA monolayer while inducing stronger adsorption in the PHA monolayer. It is believed that a lower level of solvation with less polar deposition solvents allowed for more adsorbate/substrate interaction and more intermolecular attraction. The addition of more MHA to a multilayer resulted only in stronger SEIRA peaks. As a PHA multilayer thickened there was significant structural changes represented by new bands and spectral peak shifts with greater intermolecular attraction as the multilayer approached bulk properties. Due to the range of applications involving HBA isomers, these studies could find significant applications in biochemistry, medicine, nanotechnology and environmental science.


Asunto(s)
Hidroxibenzoatos/química , Hidroxibenzoatos/farmacocinética , Metales/metabolismo , Adsorción , Isomerismo , Modelos Biológicos , Modelos Moleculares , Espectrofotometría Infrarroja/métodos , Espectrometría Raman/métodos , Propiedades de Superficie
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA